683 Capital Management’s VYNE Therapeutics VYNE Stock Holding History

683 Capital Management’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-39,744	Closed	-$994K	–	360
2021 Q3	$994K	Sell	39,744 -1,016	-2%	-$39.4K	0.04%	143
2021 Q2	$2.58M	Buy	+40,760	New	+$3.23M	0.09%	111
2021 Q1	–	Sell	-82,902	Closed	-$9.43M	–	237
2020 Q4	$9.43M	Hold	82,902	–	–	0.45%	49
2020 Q3	$9.91M	Buy	82,902 +5,816	+8%	+$679K	0.73%	34
2020 Q2	$9.6M	Buy	77,086 +49,341	+178%	+$6.68M	0.77%	30
2020 Q1	$5.35M	Buy	+27,745	New	+$8.7M	0.63%	39

Other funds holding VYNE

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

683 Capital Management's VYNE Position: Q4 2021 in Review

683 Capital Management sold out of VYNE Therapeutics (VYNE) in Q4 2021, closing a stake of 39,744 shares — an estimated $994K sold.

683 Capital Management first reported a position in VYNE in Q1 2020 and held it in 6 quarters. The position peaked at $9.91M in Q3 2020. 54 funds tracked by Wall St. Rank hold VYNE as of Q4 2021.

683 Capital Management reported no remaining VYNE Therapeutics position as of Q4 2021 after selling out during the quarter.
683 Capital Management sold 39,744 VYNE Therapeutics shares in Q4 2021, an estimated $994K.
683 Capital Management first reported a position in VYNE Therapeutics in Q1 2020 and held it in 6 quarters.
683 Capital Management's VYNE Therapeutics position peaked at $9.91M in Q3 2020.
54 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2021.

Based on 683 Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.